scholarly journals Toward a real liquid biopsy in metastatic breast and prostate cancer: Diagnostic LeukApheresis increases CTC yields in a European prospective multicenter study (CTCTrap)

2018 ◽  
Vol 143 (10) ◽  
pp. 2584-2591 ◽  
Author(s):  
Kiki C. Andree ◽  
Anouk Mentink ◽  
Leonie L. Zeune ◽  
Leon W.M.M. Terstappen ◽  
Nikolas H. Stoecklein ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Multicenter Study ◽  
Liquid Biopsy ◽  
Metastatic Breast ◽  
Prospective Multicenter Study ◽  
Cancer Diagnostic ◽  
Breast And Prostate Cancer

Abstract 1723: Diagnostic leukapheresis results in a significant increase in CTC yield in metastatic breast and prostate cancer

2017 ◽  
Author(s):  
Kiki C. Andree ◽  
Anouk Mentink ◽  
Joost F. Swennenhuis ◽  
Leon W. Terstappen ◽  
Nikolas H. Stoecklein ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Metastatic Breast ◽  
Breast And Prostate Cancer

scholarly journals Practical update for the use of bone-targeted agents in patients with bone metastases from metastatic breast cancer or castration-resistant prostate cancer

2020 ◽  
Vol 27 (4) ◽  
Author(s):  
D. Southcott ◽  
A. Awan ◽  
K. Ghate ◽  
M. Clemons ◽  
R. Fernandes
Keyword(s):  
Prostate Cancer ◽  
Bone Metastases ◽  
Metastatic Breast ◽  
Pathologic Fracture ◽  
Dose Schedule ◽  
Cord Compression ◽  
Targeted Agents ◽  
Castration Resistant Prostate Cancer ◽  
Skeletal Related Events ◽  
Breast And Prostate Cancer

Bone metastases are a significant source of morbidity and mortality for patients with breast and prostate cancer. In this review, we discuss key practical themes regarding the use of bone-targeted agents (btas) such as bisphospho­nates and denosumab for managing bony metastatic disease. The btas both delay the onset and reduce the incidence of skeletal-related events (sres), defined as any or all of a need for radiation therapy or surgery to bone, pathologic fracture, spinal cord compression, or hypercalcemia of malignancy. They have more modest benefits for pain and other quality-of-life measures. Regardless of the benefits of btas, it should always be remembered that the palliative management of meta­static bone disease is multimodal and multidisciplinary. The collaboration of all disciplines is essential for optimal patient care. Special consideration is given to these key questions: What are btas, and what is their efficacy? What are their common toxicities? When should they be initiated? How do we choose the appropriate bta? What is the appropriate dose, schedule, and duration of btas?

Evaluation of prescribing practices of denosumab and zoledronic acid in breast and prostate cancer patients at University of Chicago Medicine.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e24144-e24144
Author(s):  
Heng Yang ◽  
Randall W Knoebel ◽  
Sandeep Parsad ◽  
Emma Carroll ◽  
Walter Michael Stadler
Keyword(s):  
Breast Cancer ◽  
Prostate Cancer ◽  
Metastatic Breast Cancer ◽  
Zoledronic Acid ◽  
Cancer Patients ◽  
Metastatic Breast ◽  
Adherence Rate ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Breast And Prostate Cancer

e24144 Background: Zoledronic acid (ZA) and denosumab are both bone-modifying agents (BMAs) approved for use in patients with bone metastases with breast or prostate cancer as well as patients who are receiving aromatase inhibitors (breast cancer) or androgen deprivation therapy (prostate cancer). There are various frequencies of administration, doses, and duration of these agents depending on indication and extent of disease. Currently there is data to show that ZA can be given every 3 months in patients with metastatic breast and prostate cancer, however, there is no data that clearly indicates that denosumab every 3 months is non-inferior to every 28 days. This study aimed to analyze current prescribing patterns of ZA and denosumab in metastatic breast cancer and metastatic castration resistant prostate cancer patients at The University of Chicago Medicine (UCM). Methods: This was a retrospective study of 80 patients who received at least one dose of ZA or denosumab between July 1st 2018 to June 30th 2019 from UCM outpatient oncology clinic for the purpose of treating metastatic breast cancer or metastatic castration resistant prostate cancer in conjunction with standard antineoplastic therapy. All included patients must have bone metastases. Patients were divided into four groups by disease state (breast or prostate cancer) and BMA agent (ZA or denosumab). The primary outcome was BMA therapy adherence rate, which was defined by those who received greater than or equal to 80% of appropriately scheduled doses. Descriptive statistics were used for skeletal-related events (SREs) and BMA associated adverse effects. Results: Patients who received ZA achieved higher adherence rates (100% breast, 86% prostate) compared to patients that received denosumab (63% breast, 23% prostate). The most common reason for the lower adherence rate in denosumab groups was scheduling convenience. During the study period, there were 3, 0, 2 and 5 patients had SREs in the above four groups respectively. The predominant adverse event across all groups was hypocalcemia and two patients with prostate cancer on denosumab developed osteonecrosis of the jaw. The cost analysis showed using ZA as primary BMA agent might save up to 2.5 million dollars per year at UCM. Conclusions: The use ofZA was associated with higher adherence rates compared to denosumab. Implementing a pharmacy driven protocol for ZA use for patients with metastatic breast and prostate cancer may improve BMA regimen adherence rates and significantly reduce costs.

Trends in Metastatic Breast and Prostate Cancer — Lessons in Cancer Dynamics

2015 ◽  
Vol 373 (18) ◽  
pp. 1685-1687 ◽  
Author(s):  
H. Gilbert Welch ◽  
David H. Gorski ◽  
Peter C. Albertsen
Keyword(s):  
Prostate Cancer ◽  
Metastatic Breast ◽  
Breast And Prostate Cancer ◽  
Cancer Dynamics

Impacts of leuprolide acetate on quality of life in patients with prostate cancer: A prospective multicenter study

2010 ◽  
Vol 44 (6) ◽  
pp. 399-405 ◽  
Author(s):  
Dalsan You ◽  
In Gab Jeong ◽  
Sae Woong Kim ◽  
Byung Ha Chung ◽  
Jin Seon Cho ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Multicenter Study ◽  
Leuprolide Acetate ◽  
Prospective Multicenter Study

scholarly journals Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer

2005 ◽  
Vol 12 (4) ◽  
pp. 1051-1058 ◽  
Author(s):  
Davide Melisi ◽  
Rosa Caputo ◽  
Vincenzo Damiano ◽  
Roberto Bianco ◽  
Bianca Maria Veneziani ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Zoledronic Acid ◽  
Nude Mice ◽  
Antitumor Effect ◽  
Kinase Inhibitor ◽  
Metastatic Breast ◽  
Cyclooxygenase 2 ◽  
Cox 2 ◽  
Breast And Prostate Cancer

Biphosphonates (BPs) are widely used to inhibit osteoclastic activity in malignant diseases such as bone metastatic breast and prostate carcinoma. Recent studies reported that BPs could also cause a direct antitumor effect, probably due to their ability to interfere with several intracellular signalling molecules. The enzyme cyclooxygenase-2 (COX-2) and the epidermal growth factor receptor (EGFR) play an important role in the control of cancer cell growth and inhibitors of COX-2 and EGFR have shown antitumor activity in vitro and in vivo in several tumor types. We, and others, have previously shown that EGFR and COX-2 may be directly related to each other and that their selective inhibitors may have a cooperative effect. In the present study we have evaluated the combined effect of zoledronic acid, the most potent nitrogen-containing BP, with the COX-2 inhibitor SC-236 and the selective EGFR-tyrosine kinase inhibitor gefitinib, on breast and prostate cancer models in vitro and in xenografted nude mice. We show that combination of zoledronic acid with SC-236 and gefitinib causes a cooperative antitumor effect accompanied by induction of apoptosis and regulation of the expression of mitogenic factors, proangiogenic factors and cell cycle controllers both in vitro and in xenografted nude mice. The modulatory effect on protein expression and the inhibitory effect on tumor growth is much more potent when the three agents are used together. Since studies are ongoing to explore the antitumor effect of zoledronic acid, our results provide new insights into the mechanism of action of these agents and a novel rationale to translate this feasible combination treatment strategy into a clinical setting.

Sign in / Sign up

Export Citation Format

Share Document